Treatment of inoperable non-small cell lung carcinoma stage IIIB and IV with cisplatin, epidoxorubicin, vindesine and lonidamine: A phase II study

Tumori

Volumn 85, Issue 4, 1999, Pages 239-242

  Portalone, Luigi ^a   Lombardi, Alessandra ^a   Antilli, Antonio ^a   Cruciani, Anna Rita ^a   Magliacani, Vinicio ^a   Mugnaini, Luigi ^a   Nunziati, Francesco ^a   Perrone, Nicola ^a   Signora, Mauro ^a   Salvati, Franco ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Cisplatin; Epidoxorubicin; Lonidamine; Non small cell lung cancer; Vindesine

Indexed keywords

CISPLATIN; EPIRUBICIN; LONIDAMINE; VINDESINE;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MYALGIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA;

EID: 0032862447     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169908500405     Document Type: Article

References (23)

1. Buccheri G.F.: Chemotherapy and survival in non-small-cell lung cancer: the old vexata question. Chest, 99: 1328-1329, 1991.
2. Cellerino R., Tummarello D., Guidi F., Isidori P., Raspugli M., Biscottini B., Fatati G.: A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J. Clin. Oncol., 9: 1453-1461, 1991.
3. Cullen M.H.: Trials of radical radiotherapy versus chemotherapy plus radical radiotherapy in non-small-cell lung cancer. Semin. Oncol., 21: 34-41, 1994.
4. Del Bufalo D., Zupi G.: In vitro potentiation of epirubicin activity by Ionidamine in a human breast cancer cell line. Int. J. Oncol., 4: 737-740, 1994.
5. Dogliotti L., Berruti A., Buniva T., Zola P., Baù M.G., Farris A., Sarobba M.G., Bottini A., Alquati P., Deltetto F., Gosso P., Monzeglio C., Moro G., Sussio M., Perroni D.: Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J. Clin. Oncol., 4: 1165-1172, 1996.
6. Faulds D.: Current options in the treatment of non-small cell lung cancer. Drugs, 44: 46-59, 1992.
7. Ginsberg R.J., Kriss M.G., Armstrong I.G.: Cancer of the lung. Section 1. Non small cell lung cancer. In: Cancer: principles and practice of oncology, De Vita V.T. Jr., Hellman S., Rosenberg S.A. (Eds.), pp. 673-723, J.B. Lippicott, Philadelphia, 1993.
8. . Haskell C.M.: Chemotherapy and survival of patients with non-small cell lung cancer: a contrary view. Chest, 99: 1325-1326, 1991.
9. Hopwood P., Thatcher N.: Preliminary experience with quality of life evaluation in patients with lung cancer. Oncology, 4: 158-162, 1990.
10. Ianniello G., De Cataldis G., Comella P., Della Vittoria Scarpati M., Maiorino A., Brancaccio L., Cioffi R., Lombardi A., Carnicelli P., Tinessa V.: Cisplatin, epirubicin and vindesine with or without Ionidamine in the treatment of inoperable non-small-cell lung carcinoma. A multicenter randomized clinical trial. Cancer, 78: 63-69, 1996.
11. Miller A.B., Hoogstraten B., Staquet M., Winkler A.: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
12. Neri B., Lottini G., Bandinelli E., Cini-Neri G.: Doxorubicin plus lonidamine: in vivo metabolic effects on the rat heart. Anti-Cancer Drug, 2: 401-404, 1991.
13. Nicolson M.C., Smith I.E., Ellis P.A., Ashley S.: Effective symptom relief with moderate dose MVP (mitomycin-C, vinblastine, cisplatin) chemotherapy in advanced non-small-cell lung cancer (NSCLC) (abstract 351). Lung Cancer, 11 (suppl. 1):92, 1994.
14. Non-Small-Cell Lung Cancer Collaborative Group: Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ, 311: 899-909, 1995.
15. Pratesi G., De Cesare M., Zunino F.: Efficacy of Ionidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft. Cancer Chemother. Pharmacol., 38: 123-128, 1996.
16. Raaphorst G.P., Ko D., Feeley M.M., Danjoux C.E., Maroun J., Evans W.K.: The effect of lonidamine alone and in combination with cisplatin on in vitro growth and viability of lung squamous cell carcinoma cell lines. Anticancer Res., 11: 41-48, 1991.
17. Robustelli della Cuna G., Pedrazzoli P.: Toxicity and clinical tolerance of lonidamine. Semin. Oncol., 48: 18-22, 1991.
18. Sanguedolce R., Flandina C., Cucchiara T., Varvara F., Rausa L.: Morphological changes in the hearts of CD1 mice following chronic treatment with doxorubicin and lonidamine. Res. Commun. Chem. Pathol. Pharmacol., 82: 81-89, 1993.
19. Silvestrini R., Zaffaroni N., Villa R., Orlandi L., Costa A.: Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int. J. Cancer, 52: 813-817, 1992.
20. Souhami R.I.: Defining the role of chemotherapy in non small cell lung cancer. Ann. Oncol., 6: 317-318, 1995.
21. Souquet P.J., Chauvin P., Boissel J.P., Cellerino R., Cormier Y., Ganz P.A., Kaasa S., Pater J.L., Quoix E., Rapp E., Tummarello D., Williams J., Woods B.L., Bernard J.P.: Polychemotherapy in advanced non-small-cell lung cancer: a meta-analysis. Lancet, 342: 19-21, 1993.
22. Teicher B.A., Herman T.S., Holden S.A., Epelbaum R., Liu S., Frei E. III: Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. Cancer Res., 51: 780-784, 1991.
23. World Health Organization, WHO Handbook for reporting the Results of Cancer Treatment, WHO offset publication no. 48, Geneva, 1979.